298 related articles for article (PubMed ID: 24408116)
21. Double-blind comparison of losartan, lisinopril and hydrochlorothiazide in hypertensive patients with a previous angiotensin converting enzyme inhibitor-associated cough.
Ramsay LE; Yeo WW;
J Hypertens Suppl; 1995 Jul; 13(1):S73-6. PubMed ID: 18800460
[TBL] [Abstract][Full Text] [Related]
22. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial.
Saklayen MG; Gyebi LK; Tasosa J; Yap J
J Investig Med; 2008 Apr; 56(4):714-9. PubMed ID: 18382267
[TBL] [Abstract][Full Text] [Related]
23. Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy.
Srivastava A; Adams-Huet B; Vega GL; Toto RD
J Investig Med; 2016 Aug; 64(6):1102-8. PubMed ID: 27388615
[TBL] [Abstract][Full Text] [Related]
24. Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy.
Abe H; Minatoguchi S; Ohashi H; Murata I; Minagawa T; Okuma T; Yokoyama H; Takatsu H; Takaya T; Nagano T; Osumi Y; Kakami M; Tsukamoto T; Tanaka T; Hiei K; Fujiwara H
Hypertens Res; 2007 Oct; 30(10):929-35. PubMed ID: 18049024
[TBL] [Abstract][Full Text] [Related]
25. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.
Kurokawa K; Chan JC; Cooper ME; Keane WF; Shahinfar S; Zhang Z
Clin Exp Nephrol; 2006 Sep; 10(3):193-200. PubMed ID: 17009077
[TBL] [Abstract][Full Text] [Related]
26. The end of dual therapy with renin-angiotensin-aldosterone system blockade?
de Zeeuw D
N Engl J Med; 2013 Nov; 369(20):1960-2. PubMed ID: 24206456
[No Abstract] [Full Text] [Related]
27. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
[TBL] [Abstract][Full Text] [Related]
28. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
Hunsicker LG
J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S12-7. PubMed ID: 15369420
[TBL] [Abstract][Full Text] [Related]
29. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.
Fernández-Juárez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Lahera V; Casas L; Oliva J;
Clin J Am Soc Nephrol; 2013 Nov; 8(11):1870-6. PubMed ID: 24135218
[TBL] [Abstract][Full Text] [Related]
30. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
[TBL] [Abstract][Full Text] [Related]
31. Combined angiotensin inhibition in diabetic nephropathy.
Nikolaidou B; Lazaridis A; Doumas M
N Engl J Med; 2014 Feb; 370(8):778-9. PubMed ID: 24552332
[No Abstract] [Full Text] [Related]
32. Combined angiotensin inhibition in diabetic nephropathy.
Best M; de Wever J; Smulders Y
N Engl J Med; 2014 Feb; 370(8):778. PubMed ID: 24552331
[No Abstract] [Full Text] [Related]
33. Combined angiotensin inhibition in diabetic nephropathy.
Izumi Y; Kawahara K; Nonoguchi H
N Engl J Med; 2014 Feb; 370(8):777-8. PubMed ID: 24552330
[No Abstract] [Full Text] [Related]
34. Combined angiotensin inhibition in diabetic nephropathy.
Quiroga B; Fernández Juárez G; Luño J
N Engl J Med; 2014 Feb; 370(8):777. PubMed ID: 24552329
[No Abstract] [Full Text] [Related]
35. Combined angiotensin inhibition in diabetic nephropathy.
Fried LF; Emanuele N; Zhang JH
N Engl J Med; 2014 Feb; 370(8):779. PubMed ID: 24552328
[No Abstract] [Full Text] [Related]
36. The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone.
Schjoedt KJ
Dan Med Bull; 2011 Apr; 58(4):B4265. PubMed ID: 21466768
[TBL] [Abstract][Full Text] [Related]
37. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
Leehey DJ; Zhang JH; Emanuele NV; Whaley-Connell A; Palevsky PM; Reilly RF; Guarino P; Fried LF;
Clin J Am Soc Nephrol; 2015 Dec; 10(12):2159-69. PubMed ID: 26482258
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy.
Momeni A; Behradmanesh MS; Kheiri S; Karami Horestani M
J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):113-8. PubMed ID: 23486907
[TBL] [Abstract][Full Text] [Related]
39. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
[TBL] [Abstract][Full Text] [Related]
40. [Dual blockade of the renin-angiotensin system in diabetic patients is dangerous].
Steurer J
Praxis (Bern 1994); 2014 Feb; 103(5):289-90. PubMed ID: 24568766
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
